Refine by MP, party, committee, province, or result type.
Industry committee Yes.
October 21st, 2010Committee meeting
Richard Elliott
Industry committee Yes. These are figures that come from UNAIDS.
October 21st, 2010Committee meeting
Richard Elliott
Industry committee That's worldwide.
October 21st, 2010Committee meeting
Richard Elliott
Industry committee Africa is the most heavily affected continent, so the bulk of those deaths are happening in Africa, but it's not only Africa.
October 21st, 2010Committee meeting
Richard Elliott
Industry committee Yes, 90%
October 21st, 2010Committee meeting
Richard Elliott
Industry committee This legislation is not doing that as it stands because, as we were saying, there's been only one use of it, and that has been for an AIDS drug to one country. So we can't say this legislation is doing anything. This legislation could do something, because the legislation, as it
October 21st, 2010Committee meeting
Richard Elliott
Industry committee The Global Fund is around... It depends on each country's contribution.
October 21st, 2010Committee meeting
Richard Elliott
Industry committee Thank you. That's an excellent question. Because India now grants patents on pharmaceutical products--where it did not before 2005--in order to produce and export a generic version of a drug, you would need a mechanism like CAMR. In 2005, when India made the changes to its Paten
October 21st, 2010Committee meeting
Richard Elliott
Industry committee It would depend on the country, but most of the drugs, most of the generics, for example, that are being used to treat people are being WHO pre-qualified. That's why WHO set up that mechanism, and most developing countries that are purchasing medicines are requiring that there be
October 21st, 2010Committee meeting
Richard Elliott
Industry committee I would just add that if we have all of that infrastructure in place, but that infrastructure can't actually purchase medicines at an affordable price, what is it giving to patients? The two actually are not mutually exclusive; they need to go hand in hand. So this is about deali
October 21st, 2010Committee meeting
Richard Elliott
Industry committee There's the on-the-ground part and then there's the legal part about CAMR. Maybe we could split it up.
October 21st, 2010Committee meeting
Richard Elliott
Industry committee I would differ slightly with Dr. Kilby about the perhaps overly rosy picture regarding access here to medicines being perfect. In the U.S. there are barriers to access, but not necessarily the patent barriers. I did want to specifically speak to the legal aspect of preventing th
October 21st, 2010Committee meeting
Richard Elliott
Industry committee I can, and I actually think there are two experts who have also made a written submission to the committee, addressing some of these very specific points, two economists who have studied the pharmaceutical sector quite intensively. One thing to say in response to this claim that
October 21st, 2010Committee meeting
Richard Elliott
Industry committee Thank you. I think it's important to remember that in the one instance when, despite the flaws in CAMR, it was actually made possible to get a medicine out the door, the price the generic manufacturer offered Rwanda was competitive. It was 19.5ยข per tablet, which was the same pr
October 21st, 2010Committee meeting
Richard Elliott
Industry committee But it is not a static situation. It is dynamic.
October 21st, 2010Committee meeting
Richard Elliott